INTERNATIONAL SEARCH REPORT

International annlic

		. •	PCT/US03/2878	ž				
	ASSIFICATION OF SUBJECT MATTER							
US CL	: C12Q 1/68; C07H 21/04 : 435/6; 536/23.1, 24.3							
	o International Patent Classification (IPC) or to both	national cl	assification and IPC					
B. FIE	LDS SEARCHED		The state of the s					
Minimum de	ocumentation searched (classification system follower	d by classi	fication symbols)					
U.S. : 4	435/6; 536/23.1, 24.3	a 0) 0.1332	wanton symbols/					
-								
Documentati	ion searched other than minimum documentation to the	he extent th	at such documents are included	in the fields searched				
				and the tieres scarefied				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)								
Please See Continuation Sheet								
C. DOC	UMENTS CONSIDERED TO BE RELEVANT	•						
Category *	Citation of document, with indication, where	арргоргіац	e, of the relevant passages	Relevant to claim No.				
X	BRUNO et al. In vitro selection of DNA aptamers	BRUNO et al. In vitro selection of DNA aptamers to anthrax spores with						
 A	electrochemiluminescence detection. Biosensors & 457-464.	27.41						
••				37-41				
Α	US 5,705,340 (RASMUSSEN et al.) 06 January 19	1-41						
A	column 10, lines 28-40).							
А	US 2002/0095073 A1 (JACOBS et al.) 18 July 200 and [0267].	1-41						
				i				
			ı					
			•	i				
			.					
			· I					
Further	documents are listed in the continuation of Box C.		See patent family annex.					
S	pecial categories of cited documents:	- - -	later document published after the inter	national filing date or priority				
"A" document	defining the general state of the art which is not considered to be		date and not in conflict with the application principle or theory underlying the investigation.	tion but cited to understand the				
of particul	ar relevance	•x•	document of particular relevance; the c					
'E" carlier app	olication or patent published on or after the international filing date	•	considered novel or cannot be considered	ed to involve an inventive step				
'L' document	which may throw doubts on priority claim(s) or which is cited to		when the document is taken alone					
establish the publication date of another citation or other special reason (as specified)			"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is					
O" document referring to an oral disclosure, use, exhibition or other means			combined with one or more other such	documents, such combination				
		being obvious to a person skilled in the	· .					
priority da	published prior to the international filing date but later than the te claimed	"&"	document member of the same patent fa	mily				
Date of the ac	tual completion of the international search	Date of r	mailing of the international search	n report				
			11 MAR 2005					
2 February 2005 (22.02.2005) Iame and mailing address of the ISA/US			ed officer	01 11				
Mail Stop PCT, Attn: ISA/US			Callany Y Lot	Lans				
Commissioner for Patents P.O. Box 1450			COUNTY OF THE SECOND	100 00 150000				
Alexa	andria, Virginia 22313-1450	ј етећиоц	ie No. (571) 272-1600 PATER	EXAMINEN				
	(703) 305-3230							
rm PCT/ISA/	210 (second sheet) (July 1998)							

INTERNATIONAL SEARCH REPORT

PC.	[/]	US 03	/28	782

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-41, drawn to a method of identifying a nucleic acid ligand and a composition comprising a nucleic acid ligand, particularly said ligand of SEQ ID No. 4.

Group II, claim(s) 42-47, drawn to a composition comprising a nucleic acid ligand, particularly said ligand of SEQ ID Numbers 5 and 6.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

37 CFR 1.475 which governs Lack of Unity practice in International and National Stage Application recites that an international or a national application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn to only one of the following combination of categories:

- 1) a product and a process specially adapted for the manufacture of said product; or
- 2) a product and process of use of said product; or
- 3) a product and a process specially adapted for the manufacture of said product; and a use of said product; or
- 4) a process and an apparatus or means specifically designed for carrying out the said process; or
- 5) a product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.

Instant application contains two different products (i.e., composition) comprising two different nucleic acid ligands (as denoted by their different SEQ ID Numbers). 37 CFR 1.475 states that if an application contains claims to "more or less than one of the combination of categories of invention set forth in paragraph (recited above), unity of invention might not be present. Since the first method and the first composition, categorized by a single category of invention, have already been grouped together, the additional composition would lack unity of invention as being drawn to an additional category. Additionally, the two compositions would lack unity of invention as the special technical feature critical to the invention, that is the SEQ ID Number, is not shared between the two compositions, as their sequences are clearly different (pages 31 and 35).

Continuation of B. FIELDS SEARCHED Item 3:

Non Patent Literature Databases

Patent Databases (USPT, USPGP, EPO, JPO, DERWENT, IBM-TDB)

search terms: anthrax, anthracis, lactamase, matallo and lactamase, SELEX, aptamers, inhibit, treatment.

Form PCT/ISA/210 (second sheet) (July 1998)